In 2023, a paper published in BMJ Tobacco Control examined intravaginal tobacco use among women in The Gambia, a growing trend in Sub-Saharan African countries that received little scientific attention. A subsequent study of the topic was launched in 2024, to be completed by the end of 2025.
In collaboration with research partners in the United States and The Gambia, the study looks at what motivates women who use tobacco intravaginally. It also documents tobacco use behaviors and assesses the chemical composition (including nicotine content) and level of toxicity of the products. The study examines both the sociocultural motivations behind the practice and the chemical composition of the tobacco used.
Preliminary findings reveal that women use intravaginal tobacco for various reasons, including treating vaginal yeast infection, enhancing sexual pleasure, improving pregnancy and labor outcomes, and treating various health conditions including hypertension, asthma, and infertility. Findings also show that the product is often marketed by local vendors as traditional medicine, but may contain dangerous additives, including baobab ash, caustic soda, cannabis, and shea butter, raising concerns about its potential toxicological effects.
The study is funded by the Bloomberg Initiative to Reduce Tobacco Use through the CDC Foundation, with a grant from Bloomberg Philanthropies.
